Pediatric Dermatology

Researchers explored the efficacy of a multistep treatment strategy in a younger patient population.

Researchers in China reviewed topical modalities, minoxidil solutions, tofacitinib, and microneedling for pediatric AA.

Among dermatologists specializing in pediatric alopecia areata, a survey found that class 1 and 2 topical corticosteroids are the preferred first-line therapy.

Factors such as nutritional compromise, low levels of vitamin D, and more, negatively affect bone metabolism in this patient population.

In this week’s Pointers With Portela, the 208SkinDoc gives his recommendations for a pre-teen skin care routine.

Additionally, investigators found that several patients in the review had rosacea induced or exacerbated by the use of topical corticosteroids on the face.

Lisa Swanson, MD, PhD, delves into clinical pearls from her SDPA fall conference sessions on infantile hemangiomas and challenging cases in pediatric dermatology.

Francesca Tenconi, president and CEO of Children’s Skin Disease Foundation and Camp Wonder, presented at Fall Clinical 2023 about the challenges of chronic skin conditions in children.

Factors determining severe levels of stress included uncertainty about treatment progress, diagnosis, and treatment path.

In studying pediatric patients with skin of color in a center specializing in pigment and skin of color, investigators described a paucity of literature of such nature.

The approval provides pediatric patients with a steroid-free topical therapy.

As cold weather is approaching for much of the country, it is crucial for dermatologists, pediatricians, and families to work together for proper pediatric atopic dermatitis care.

Verrica’s statement follows the FDA’s warning from June 1, 2023.

As your youngest patients begin the return to the classroom, pediatric dermatologist Latanya Benjamin, MD, FAAD, FAAP, offers perspectives in education and skin care tips.

With hormonal fluctuations, constantly changing schedules, and various afterschool activities, addressing the specific needs of teenage skin becomes essential to promote a lifetime of proper skin care practices.

Peter Lio, MD, discusses pearls and takeaways from the atopic dermatitis panel he participated in at the 2023 Society of Pediatric Dermatology meeting.

Verrica’s VP-102 is the first FDA-approved treatment for molluscum lesions.

Researchers conducted a systematic review and meta-analysis of probiotic treatment efficacy in children with atopic dermatitis.

The TRuE-AD3 study met its primary endpoint of IGA-TS improvement from baseline at week 8.

Adelaide Hebert, MD, reviewed ichthyosis, epidermolysis bullosa, molluscum contagiosum, and more at the 2023 Fall Clinical Dermatology Conference for PAs and NPs.

Benjamin encouraged attendees at SCALE 2023 to think beyond just topicals for pediatric acne.

Dermatology advanced practice providers work alongside physicians to improve patient care and access.

Novan’s expected PDUFA date is January 5, 2024.

Treatment is not mandatory and, in fact, clinicians are still without an FDA-approved treatment option, but parents often insist on some sort of action.

“So much new in the world of pediatric dermatology—new and novel treatments for atopic dermatitis, hemangiomas, childhood blistering diseases, warts. We are practicing during the Golden Age of dermatology,” Swanson says.